本文選題：FOLFIRINOX + 胰腺癌　； 參考：《浙江大學(xué)》2017年碩士論文

【摘要】：目的:評(píng)估改良FOLFIRINOX方案治療進(jìn)展期胰腺癌的臨床療效和安全性。方法:本研究共納入2014年4月至2016年12月在本中心接受改良FOLFIRINOX(modified-FOLFIRINOX,mFOLFIRINOX)(無(wú) 5-氟尿嘧啶靜推,80%原劑量奧沙利鉑,75%原劑量伊立替康)化療的進(jìn)展期胰腺癌(advanced pancreatic cancer,APC)患者68例(LAPC 28例,MPC 40例),評(píng)估m(xù)FOLFIRINOX方案化療后的緩解率、安全性、轉(zhuǎn)化率、手術(shù)信息、整體生存率、無(wú)進(jìn)展生存時(shí)間等。結(jié)果:68例APC患者對(duì)mFOLFIRINOX方案化療總體反應(yīng)率為26.5%;最常見(jiàn)的3/4級(jí)副反應(yīng)為中性粒細(xì)胞減少(26.5%)和貧血(14.75%);化療后11例LAPC實(shí)現(xiàn)轉(zhuǎn)化并接受了手術(shù)(轉(zhuǎn)化率39.3%);LAPC組病人中位生存時(shí)間(overall survival,OS)和無(wú)進(jìn)展生存時(shí)間(progression free survival,PFS)均為 13 個(gè)月,MPC組中位生存時(shí)間和中位無(wú)進(jìn)展生存時(shí)間分別為10個(gè)月和9個(gè)月。結(jié)論:本中心應(yīng)用mFOLFIRINOX化療方案能顯著改善中國(guó)APC人群的對(duì)化療藥毒副反應(yīng)的耐受性,同時(shí)保持與原方案方案相仿的療效和讓人可接受的毒性反應(yīng)發(fā)生率。這些數(shù)據(jù)可能為FOLFIRINOX在中國(guó)用于治療進(jìn)展期胰腺癌患者提供指導(dǎo)。
[Abstract]:Objective: to evaluate the efficacy and safety of modified FOLFIRINOX regimen in the treatment of advanced pancreatic cancer. Methods: from April 2014 to December 2016, 68 patients with advanced pancreatic cancer of advanced pancreatic cancer received modified FOLFIRINOXX modified FOLFIRINOXMFOLFIRINOXX (no 5-fluorouracil 80% oral oxaliplatin 75% primordial dose of Ilitecan) in our center from April 2014 to December 2016 were enrolled in this study. The remission rate of 28 patients with MPC was evaluated after chemotherapy with mFOLFIRINOX regimen (n = 40). Safety, conversion rate, surgical information, overall survival rate, progression-free survival time, etc. Results the overall response rate of 68 patients with APC to mFOLFIRINOX regimen was 26.5; the most common side effects of grade 3 / 4 were neutropenia 26.5) and anemia 14.7550. After chemotherapy, 11 cases of LAPC were transformed and underwent surgery (the conversion rate was 39.3%) and the median survival rate of the patients in the LAPC group was 39.3%. The median survival time and progression free survival time of MPC group were 10 months and 9 months, respectively. Conclusion: mFOLFIRINOX regimen in our center can significantly improve the tolerance to side effects of chemotherapy in Chinese APC population, while maintaining the same efficacy and acceptable incidence of toxic reactions as the original regimen. These data may provide guidance for the use of FOLFIRINOX in the treatment of advanced pancreatic cancer in China.
【學(xué)位授予單位】：浙江大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類(lèi)號(hào)】：R735.9
，

本文編號(hào)：1946413